On September 28, 2022, Jonathan Thomas Jorgl filed a definitive proxy statement and is mailing a letter to stockholders in connection with AIM ImmunoTech Inc.'s 2022 annual meeting of stockholders to be held on November 3, 2022. In the letter, Jonathan Thomas Jorgl expressed his view that this is an effort to divert shareholders attention from the key issues confronting the Board and harming stockholders, including a massive decline of the Company share price, excessive executive compensation, and a self-serving governance structure with no accountability to stockholders. Jonathan Thomas Jorgl also urges all of the Company's stockholders to vote on Jonathan Thomas Jorgl's proxy card to elect his nominees, Robert L. Chioini and Michael Rice, to initiate a turnaround in the Company that is desperately needed so that it is managed and overseen in a manner consistent with the stockholders' best interests.